|
WO2021067297A1
|
|
Treatment of alcoholic hepatitis
|
|
WO2021011896A1
|
|
Long-acting formulations and vehicles
|
|
US2018117016A1
|
|
Depot formulations
|
|
CN110214029A
|
|
Long-acting formulation
|
|
AU2017305305A1
|
|
Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
|
|
TW201818944A
|
|
Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions
|
|
EP3481381A1
|
|
Oral dosage form with drug composition, barrier layer and drug layer
|
|
TW201811374A
|
|
Depot formulations
|
|
AU2016200966A1
|
|
Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
|
|
CA2932290A1
|
|
Compositions comprising antioxidant, fluid dispensers, and methods involving the same
|
|
WO2015088990A1
|
|
Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
|
|
CN105121438A
|
|
Compositions with thixotropy and enhanced dissolution reproducibility and stability
|
|
TW201521769A
|
|
Compositions with a rheological modifier to reduce dissolution variability
|
|
CN105163719A
|
|
Injectable controlled release composition comprising high viscosity liquid carrier
|
|
US2014011842A1
|
|
Oral Pharmaceutical Dosage Forms
|
|
AU2013202707A1
|
|
Oral pharmaceutical dosage forms
|
|
AU2013202598A1
|
|
Sustained release small molecule drug formulation
|
|
AU2013202476A1
|
|
Improved depot formulations
|
|
AU2013202352A1
|
|
Transdermal delivery systems comprising bupivacaine
|
|
US2014294977A1
|
|
Radiation-Sterilized Biodegradable Drug Delivery Composition
|
